DMAA, banned for its adverse cardiovascular effects) (Evans-Brown et al, 2012)
Published clinical trials, conducted under medical supervision, also document potential side effects such as gastrointestinal side effects and, in rare cases, pancreatitis
Wegovy can drive nearly 15% weight loss over a year and a half
Both tirzepatide and semaglutide have been shown to reduce weight for patients who are overweight or obese in randomized controlled trials
Peptides are susceptible to degradation through processes such as oxidation, hydrolysis, or enzymatic cleavage
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci 58(20):17771784